SuperworthMoonLake Immunotherapeutics EPS MLTX
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$3.84
- Latest quarter, Q2 FY26
- −$0.84
- Fiscal year 2025
- −$3.52
MoonLake Immunotherapeutics' earnings per share was −$3.84 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.84.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.52 | n/a |
| FY2024 | −$1.89 | n/a |
| FY2023 | −$0.76 | n/a |
| FY2022 | −$4.21 | n/a |
| FY2021 | −$5.67 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.84 | n/a | −$3.84 | |
| Q1 FY26 | −$0.98 | n/a | −$3.87 | |
| Q4 FY25 | −$0.92 | n/a | −$3.52 | |
| Q3 FY25 | −$1.10 | n/a | −$3.32 | |
| Q2 FY25 | −$0.87 | n/a | −$2.78 | |
| Q1 FY25 | −$0.63 | n/a | −$2.30 | |
| Q4 FY24 | −$0.72 | n/a | −$1.89 | |
| Q3 FY24 | −$0.56 | n/a | −$1.29 | |
| Q2 FY24 | −$0.39 | n/a | −$0.91 | |
| Q1 FY24 | −$0.22 | n/a | −$0.75 | |
| Q4 FY23 | −$0.12 | n/a | −$0.76 | |
| Q3 FY23 | −$0.18 | n/a | −$1.07 |
Against its peers
Companies in Drug Manufacturers - General nearest MoonLake Immunotherapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MLTXMoonLake Immunotherapeutics | −$3.84 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| ABUSArbutus Biopharma | $0.78 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| CRMDCorMedix | $2.13 | +184% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| ZVRAZevra Therapeutics | $0.93 | |
| Peer median | $1.61 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on MoonLake Immunotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.